Eisai gets Japanese marketing approval for Treakisym
Treakisym is an anticancer agent that exhibits both nitrogen mustard-derived alkylating activity and antimetabolic-like activity. Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.